



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/924,400	08/07/2001	Tony N. Frudakis	210121.419C12	7385

500 7590 01/19/2006

SEED INTELLECTUAL PROPERTY LAW GROUP PLLC  
701 FIFTH AVE  
SUITE 6300  
SEATTLE, WA 98104-7092

EXAMINER

ZEMAN, MARY K

ART UNIT	PAPER NUMBER
----------	--------------

1631

DATE MAILED: 01/19/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/924,400	FRUDAKIS ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Mary K. Zeman	1631	

All participants (applicant, applicant's representative, PTO personnel):

(1) Mary K. Zeman (USPTO). (3)\_\_\_\_\_.

(2) Julie Urvater (Appl Rep). (4)\_\_\_\_\_.

Date of Interview: 13 January 2006.

Type: a) ☒ Telephonic b) ☐ Video Conference  
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.  
If Yes, brief description: \_\_\_\_\_.

Claim(s) discussed: 15 and 18.

Identification of prior art discussed: Frudakis 98/45328.

Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: see attached.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

*See Attached*

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Examiner's signature, if required

## Summary of Record of Interview Requirements

### Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record

A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

### Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews

#### Paragraph (b)

In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

#### 37 CFR §1.2 Business to be transacted in writing.

All business with the Patent or Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an Interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiners Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:

- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case. It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.

A complete and proper recordation of the substance of any interview should include at least the following applicable items:

- 1) A brief description of the nature of any exhibit shown or any demonstration conducted,
- 2) an identification of the claims discussed,
- 3) an identification of the specific prior art discussed,
- 4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
- 5) a brief identification of the general thrust of the principal arguments presented to the examiner,  
(The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
- 6) a general indication of any other pertinent matters discussed, and
- 7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.

### Examiner to Check for Accuracy

If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiner's version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, "Interview Record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.

Art Unit: 1631

Interview Summary, Attachment:

1/13/06

Issues regarding the rejections of record in this application were discussed. Potential claim language amendments to obviate the enablement rejection were discussed. Possible amendments to overcome the art and indefiniteness rejections were also discussed. Applicant was advised that amendments cannot introduce new matter. The examiner probed the file for the alignment of the claimed sequences with the applied prior art. In the IFW record, 11/8/02, in the Examiner Search Notes, the Examiner identified the original alignments relied upon. WO 98/45328 Frudakis et al, AAV68996, #188 shows approximately 300 contiguous nucleotides in common with SEQ ID NO: 302. In reviewing this file, the next sequence alignment was discovered: WO 98/45328 also discloses AAV68995, #187, which has approximately 650+ contiguous nucleotides in common with SEQ ID NO: 303.

Illustrative of the issues which may be applied again in the future with the oligonucleotide claim and the stretches of polyA in both sequences are the alignments of SEQ ID NO: 303 with AQ204617, AA533501, AQ063365, AI344928 and AI 344936. Each of these disclose short stretches of contiguous sequence in common with SEQ ID NO: 303.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mary K Zeman whose telephone number is (571) 272 0723

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel, PhD can be reached on (571) 272 0718. The fax phone number for the organization where this application or proceeding is assigned is 571 273 8300.


Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of

Art Unit: 1631

the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

  
MARY K. ZEMAN  
PRIMARY EXAMINER  
APR 16 31  
1/13/06

RESULT 40  
AAV68996  
ID AAV6

Claim 1, Page 138-139, 173pp; English.

AAV68800 to AAV68998 represent nucleotide sequences which encode human breast tumour specific polypeptides. Detection or measurement of human breast tumour specific polypeptides and nucleotide sequences, or the corresponding RNA in a sample, is used for diagnosis and monitoring of breast cancer. Human breast tumour specific polypeptides and nucleotide sequences, and the vectors containing the DNAs, are also useful in vaccines for inhibiting development (for prevention or therapy) of breast cancer. The polypeptides may also be used to raise monoclonal antibodies, used as immunoassay reagents.

Sequence 1853 BP; 521 A; 381 C; 492 G; 431 T; 28 other:

Query Match 12.4% Score 252; DB 19; Length 1853; Best Local Similarity 99.7% Pred. No. 8,9e-86; Matches 302; Conservative 0; Mismatches 1; Indels 0; Gaps 0

34 TCTTCTGTGAAGAACCATTTGGTCTCAGAGACAGATGGCCAGTGGTCCCTTGC 93  
256 TCTTCTGTGAAGAACCATTTGGTCTCAGAGACAGATGGCCAGTGGTCCCTTGC 315  
94 TTCCCTGTGTGAG 153  
316 TTCCCTGTGTGAG 375  
154 TGTCTATGAGACACTCAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 213  
376 TGTCTATGAG 435  
214 TGCAGGGGAGTGGCAG 273  
436 TGCAGGGGAGTGGCAG 495  
274 AAGGACTCAG 333  
496 AAGGACTCAG 555  
334 AGC 336  
556 AGC 558

RESULT 41  
AAC81007  
ID AAC81007 standard; cDNA: 1853 BP.  
AAC81007:  
13-FEB-2001 (first entry)  
Human B1A91 antigen protein coding exon cDNA SEQ ID NO: 295.  
Human breast tumour-specific antigen: cytosolic; vaccine:  
breast cancer; B1A91; B1A91; B1A91; 5S.  
Homo sapiens  
MO200061753-A2.  
19-OCT-2000.  
07-APR-2000; 2000MO-US09312.  
09-APR-1999; 99US-0289198.  
28-OCT-1999; 99US-0429755.  
23-MAR-2000; 2000US-0534825.  
(CORI-) CORIXA CORP.  
Frudakis TN, Smith JM, Reed SG, Misher LE, Retter AN, Dillon DC;

Claim 1, Page 138-139, 173pp; English.

AAV68800 to AAV68998 represent nucleotide sequences which encode human breast tumour specific polypeptides. Detection or measurement of human breast tumour specific polypeptides and nucleotide sequences, or the corresponding RNA in a sample, is used for diagnosis and monitoring of breast cancer. Human breast tumour specific polypeptides and nucleotide sequences, and the vectors containing the DNAs, are also useful in vaccines for inhibiting development (for prevention or therapy) of breast cancer. The polypeptides may also be used to raise monoclonal antibodies, used as immunoassay reagents.

Sequence 1853 BP; 521 A; 381 C; 492 G; 431 T; 28 other:

Query Match 12.4% Score 252; DB 19; Length 1853; Best Local Similarity 99.7% Pred. No. 8,9e-86; Matches 302; Conservative 0; Mismatches 1; Indels 0; Gaps 0

34 TCTTCTGTGAAGAACCATTTGGTCTCAGAGACAGATGGCCAGTGGTCCCTTGC 93  
256 TCTTCTGTGAAGAACCATTTGGTCTCAGAGACAGATGGCCAGTGGTCCCTTGC 315  
94 TTCCCTGTGTGAG 153  
316 TTCCCTGTGTGAG 375  
154 TGTCTATGAGACACTCAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 213  
376 TGTCTATGAG 435  
214 TGCAGGGGAGTGGCAG 273  
436 TGCAGGGGAGTGGCAG 495  
274 AAGGACTCAG 333  
496 AAGGACTCAG 555  
334 AGC 336  
556 AGC 558

RESULT 41  
AAC81007  
ID AAC81007 standard; cDNA: 1853 BP.  
AAC81007:  
13-FEB-2001 (first entry)  
Human B1A91 antigen protein coding exon cDNA SEQ ID NO: 295.  
Human breast tumour-specific antigen: cytosolic; vaccine:  
breast cancer; B1A91; B1A91; B1A91; 5S.  
Homo sapiens  
MO200061753-A2.  
19-OCT-2000.  
07-APR-2000; 2000MO-US09312.  
09-APR-1999; 99US-0289198.  
28-OCT-1999; 99US-0429755.  
23-MAR-2000; 2000US-0534825.  
(CORI-) CORIXA CORP.  
Frudakis TN, Smith JM, Reed SG, Misher LE, Retter AN, Dillon DC;

OS Homo sapiens.  
 PN W0200130152-A2.  
 XX 29-NOV-2001.  
 XX 22-MAY-2001. 2001MO-US16776.  
 XX  
 XX 24-MAY-2000. 2000US-0537505.  
 XX 08-JUN-2000. 2000US-0539583.  
 XX 26-OCT-2000. 2000US-0639295.  
 XX 16-MAR-2001. 2001US-0810936.  
 XX  
 XX (CORI) CORIXA CORP  
 XX  
 XX Fradette TM, Reed SC, Smith JM, Misher LE, Dillon DC, Retter MW;  
 PI Wang A, Shelly RM, Harlocker SL, Day CH;  
 XX WPI: 2002-089919/12.  
 XX P-PSDB: AAU74390.  
 XX  
 XX New breast tumour proteins and polynucleotides encoding them, useful for  
 PT treating and/or preventing cancer, particularly breast cancer, and for  
 PT eliciting humoral and/or cellular immune response  
 XX  
 PS Claim 1: Page 239; 245pp: English.  
 XX  
 XX The invention relates to novel breast tumour polynucleotides and  
 CC polypeptides. The polypeptides and polynucleotides are useful in  
 CC pharmaceutical compositions for treating and/or preventing cancer,  
 CC particularly breast cancer, and for eliciting an immune response,  
 CC particularly humoral and/or cellular immune response. The polynucleotides  
 CC may be used as probes or primers for nucleic acid hybridisation, in the  
 CC design and preparation of ribozyme molecules for inhibiting expression of  
 CC tumour polypeptides and proteins, and in recombinant DNA molecules to  
 CC direct expression of a polypeptide in host cells. AAS9570-AAS9888  
 CC represent novel human breast cancer protein coding sequences and  
 CC PCR primers of the invention.  
 XX  
 SO Sequence 1155 BP: 346 A; 253 C; 296 G; 260 T; 0 other:  
 Query Match 47.8%; Score 975; DB 24; Length 1155;  
 Best Local Similarity 99.7%; Pred. No. 0;  
 Matches 1155; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 Oy 1 ATGCGTGTGAGGTGATTCATGCGCGCTGCTCTCTGTGAAGAACCATTTGCTCTC 60  
 Db 1 ATGCGTGTGAGGTGATTCATGCGCGCTGCTCTCTGTGAAGAACCATTTGCTCTC 60  
 Oy 61 AGGAGCAAGATGGGCAAGTGGTCCGCTTCCCTGCTGAGGAGAGCGCGAAG 120  
 Db 61 AGGAGCAAGATGGGCAAGTGGTCCGCTTCCCTGCTGAGGAGAGCGCGAAG 120  
 Oy 121 AGCAAGTGGGCACTTCTGAGAGACGACGACACTCTGCTATGAAGACACTGAGAGCAG 180  
 Db 121 AGCAAGTGGGCACTTCTGAGAGACGACGACACTCTGCTATGAAGACACTGAGAGCAG 180  
 Oy 181 ATGGGCAAGTGGTGGGCACTTCTGAGAGACGACGACACTCTGCTATGAAGACACTGAGAGCAG 240  
 Db 181 ATGGGCAAGTGGTGGGCACTTCTGAGAGACGACGACACTCTGCTATGAAGACACTGAGAGCAG 240  
 Oy 241 GGGGCTTCTGAGAGACGACGACACTCTGCTATGAAGACACTGAGAGCAG 300  
 Db 241 GGGGCTTCTGAGAGACGACGACACTCTGCTATGAAGACACTGAGAGCAG 300  
 Oy 301 TGGTGTGCGCACTCTTCCCTGCTGAGAGAGGAGGAGAGAGAGAGAGAGAGAGAGAGAGAG 360  
 Db 301 TGGTGTGCGCACTCTTCCCTGCTGAGAGAGGAGGAGAGAGAGAGAGAGAGAGAGAGAGAG 360  
 Oy 361 GGAGACTAGAGTACAGTCTTCTGAGAGAGGAGGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 420  
 Db 361 GGAGACTAGAGTACAGTCTTCTGAGAGAGGAGGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 420

Oy 421 GACAACTCCACAGAGCTGCTGCTGGGGAAGTCCCAAGAAAGAGTCTGCTCTC 480  
 Db 421 GACAACTCCACAGAGCTGCTGCTGGGGAAGTCCCAAGAAAGAGTCTGCTCTC 480  
 Oy 481 CTCAGGAGACTGAGTGAACAG 540  
 Db 481 CTCAGGAGACTGAGTGAACAG 540  
 Oy 541 TCTGCAATGGGATTCAGAGAGTGAAGTCTCTCTGAGAGAGAGAGAGAGAGAGAGAGAGAG 600  
 Db 541 TCTGCAATGGGATTCAGAGAGTGAAGTCTCTCTGAGAGAGAGAGAGAGAGAGAGAGAGAG 600  
 Oy 601 GTCTTGAACAAAG 660  
 Db 601 GTCTTGAACAAAG 660  
 Oy 661 TGTGCTTAAATGTTGCTGAG 720  
 Db 661 TGTGCTTAAATGTTGCTGAG 720  
 Oy 721 ACCACTTGCACAG 780  
 Db 721 ACCACTTGCACAG 780  
 Oy 781 TATGCTGCTAAATGAG 840  
 Db 781 TATGCTGCTAAATGAG 840  
 Oy 841 CATGAGCAAAAG 900  
 Db 841 CATGAGCAAAAG 900  
 Oy 901 CTGATAGATATGAG 960  
 Db 901 CTGATAGATATGAG 960  
 Oy 961 GTGACCTTCTGAG 1020  
 Db 961 GTGACCTTCTGAG 1020  
 Oy 1021 GCCAAGAGATATGCTGTTCTGAG 1080  
 Db 1021 GCCAAGAGATATGCTGTTCTGAG 1080  
 Oy 1081 AAG 1128  
 Db 1081 AAG 1128  
 RESULT 30  
 AAV68995  
 ID AAV68995 standard; DNA: 1512 BP.  
 XX  
 XX AAV68995:  
 XX  
 XX 22-JAN-1999 (first entry)  
 XX  
 XX DNA molecule encoding a breast tumour specific polypeptide #187.  
 XX  
 XX Human: breast cancer; breast tumour tissue; diagnosis: treatment;  
 XX vaccine: epitope; endogenous; retroviral element: 88.  
 XX  
 XX Homo sapiens.  
 XX  
 XX W09845328-A2.  
 XX  
 XX 15-OCT-1998.  
 XX  
 XX 09-APR-1998: 98MO-US06939.  
 XX  
 XX 11-DEC-1997: 97US-0991789.  
 XX  
 XX 09-APR-1997: 97US-0838762.  
 XX

INT SUMMARY

PA (CORI-) CORIXA CORP.  
XX Prudakis TN, Reed SG, Smith JM;  
XX WPI: 1998-557473/47.  
DR

PT New DNA sequences isolated from endogenous human retroviral element  
PT - and related vectors, transformed cells, proteins and antibodies,  
PT useful for diagnosis, treatment and prevention of breast cancer.  
XX  
PS Claim 1: Page 137-138; 173pp; English.

CC AAV68800 to AAV68998 represent nucleotide sequences which encode human  
CC breast tumour specific polypeptides. Detection or measurement of  
CC human breast tumour specific polypeptides and nucleotide sequences,  
CC or the corresponding RNA in a sample, is used for diagnosis and  
CC monitoring of breast cancer. Human breast tumour specific polypeptides  
CC and nucleotide sequences, and the vectors containing the DNAs, are also  
CC useful in vaccines for inhibiting development (for prevention or  
CC therapy) of breast cancer. The polypeptides may also be used to  
CC raise monoclonal antibodies, used as immunoassay reagents.  
XX  
SQ Sequence 1512 BP; 406 A; 301 C; 393 G; 399 T; 13 other:

Query Match 24.1% Score 491; DB 19; Length 1512;  
Best Local Similarity 99.4% Pred. No. 6,4e-180;  
Matches 691; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 34 TCTTCTGTAAGAACCATTTGGTCTGACAGCAGAGTGGCGACAGTGTGCTGCCGTTGC 93  
DB 256 TCTTCTGTAAGAACCATTTGGTCTGACAGCAGAGTGGCGACAGTGTGCTGCCGTTGC 315  
OY 94 TTCCCTGTCAGAGGAGAGCCGCAAGACCAAGTGGCGACTTCTGAGACACAGAC 153  
DB 316 TTCCCTGTCAGAGGAGAGCCGCAAGACCAAGTGGCGACTTCTGAGACACAGAC 375  
OY 154 TCTGCTATGAGAGACTGACAGCAGAGTGGCGACTTCTGAGACACAGAC 213  
DB 376 TCTGCTATGAGAGACTGACAGCAGAGTGGCGACTTCTGAGACACAGAC 435  
OY 214 TGCAGGGGAGAGTGGCGCAAGACCAAGTGGCGCTTCTGAGACACAGACACTTCTATG 273  
DB 436 TGCAGGGGAGAGTGGCGCAAGACCAAGTGGCGCTTCTGAGACACAGACACTTCTATG 495  
OY 274 AGACACTGAGAACCAAGATGAGGCAAGTGGCGCTTCTGAGACACAGACACTTCTATG 333  
DB 496 AGACACTGAGAACCAAGATGAGGCAAGTGGCGCTTCTGAGACACAGACACTTCTATG 555  
OY 334 AGCGGCAAGACCAAGATGAGGCGCTTCTGAGACACAGACACTTCTATGAGCC 393  
DB 556 AGCGGCAAGACCAAGATGAGGCGCTTCTGAGACACAGACACTTCTATGAGCC 615  
OY 394 AGTACCAAGTGGCGTGGAGAGATGTCGACCAAGTGGCGCTTCTGAGACACAGACACTTCTATG 453  
DB 616 AGTACCAAGTGGCGTGGAGAGATGTCGACCAAGTGGCGCTTCTGAGACACAGACACTTCTATG 675  
OY 454 GTCCCGAAGAGATGTCGACCAAGTGGCGCTTCTGAGACACAGACACTTCTATG 513  
DB 676 GTCCCGAAGAGATGTCGACCAAGTGGCGCTTCTGAGACACAGACACTTCTATG 735  
OY 514 CAAAGAGACACTGTCATCTGAGGCTTCTGAGACCAAGATGAGATGAGTAAATC 573  
DB 736 CAAAGAGACACTGTCATCTGAGGCTTCTGAGACCAAGATGAGTAAATC 795  
OY 574 CTGCTGACAGAGATGTCATCTGAGGCTTCTGAGACCAAGATGAGTAAATC 633  
DB 796 STGCTGACAGAGATGTCATCTGAGGCTTCTGAGACCAAGATGAGTAAATC 855  
OY 634 AAGGCGCTTCTGAGGAGAGATGAGTAAATGCTTCTGAGACCAAGTAAATC 693  
DB 856 AAGGCGCTTCTGAGGAGAGATGAGTAAATGCTTCTGAGACCAAGTAAATC 915  
OY 694 CCAATATTCAGATGATGAGTAAATCAGTCT 728

DB 916 CCAATATTCAGATGATGAGTAAATCAGTCT 950

RESULT 31  
AACB1006  
ID AACB1006 standard; cDNA; 1512 BP.  
XX  
AC AACB1006;  
XX  
DT 13-FEB-2001 (first entry)  
XX  
DE Human B11A1 antigen protein coding exon cDNA SEQ ID NO: 294.  
XX  
KW Human: breast tumour-specific antigen; cytosolic; vaccine;  
KW breast cancer: B18A1; B11A1; B15A1; ss.  
XX  
OS Homo sapiens.  
XX  
PN W020061753-42.  
XX  
PD 19-OCT-2000.  
XX  
PF 07-APR-2000; 2000WO-US09312.  
XX  
PR 09-APR-1999; 98US-0289198.  
PR 28-OCT-1999; 98US-0429755.  
PR 23-MAR-2000; 2000US-0534825.  
XX  
PA (CORI-) CORIXA CORP.  
PI Prudakis TN, Smith JM, Reed SG, Misher LE, Retter MW, Dillon DC;  
PI WPI: 2000-628403/60.  
XX  
DR

PT An isolated polypeptide comprising an immunogenic portion of a breast  
PT tumor protein used for inhibiting the development of cancer, especially  
PT breast cancer, and monitoring cancer progression in a patient.  
PS Claim 4: Page 172; 187pp; English.

CC The present sequence is given in a specification relating to compositions  
CC and methods for the treatment and diagnosis of breast cancer. Nucleotide  
CC sequences that are preferentially expressed in breast tumour tissue, and  
CC the polypeptides encoded by such nucleotide sequences, are used in  
CC compositions and vaccines to inhibit the development of cancer,  
CC especially breast cancer. The progression of a cancer may be monitored by  
CC carrying out detection of tumour-specific antigens at subsequent time  
CC points and comparing the results from the different time points.  
CC CD4+ and/or CD8+ T-cells isolated from the cancer patient may be treated  
CC with tumour-specific polypeptides, polynucleotides encoding the  
CC polypeptides or antigen presenting cells expressing the polypeptides. The  
CC cells are then administered to the patient to inhibit development of  
CC cancer.

Sequence 1512 BP; 406 A; 301 C; 393 G; 399 T; 13 other:  
Query Match 24.1% Score 491; DB 21; Length 1512;  
Best Local Similarity 99.4% Pred. No. 6,4e-180;  
Matches 691; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 34 TCTTCTGTAAGAACCATTTGGTCTGACAGCAGAGTGGCGACAGTGTGCTGCCGTTGC 93  
DB 256 TCTTCTGTAAGAACCATTTGGTCTGACAGCAGAGTGGCGACAGTGTGCTGCCGTTGC 315  
OY 94 TTCCCTGTCAGAGGAGAGCCGCAAGACCAAGTGGCGACTTCTGAGACACAGAC 153  
DB 316 TTCCCTGTCAGAGGAGAGCCGCAAGACCAAGTGGCGACTTCTGAGACACAGAC 375  
OY 154 TCTGCTATGAGAGACTGACAGCAGAGTGGCGACTTCTGAGACACAGAC 213  
DB 376 TCTGCTATGAGAGACTGACAGCAGAGTGGCGACTTCTGAGACACAGAC 435

③ INT. SUMMARY



GenCore version 5.1.3  
Copyright (c) 1993 - 2002 Compugen Ltd.

OM nucleic - nucleic search, using SW model

Run on: November 8, 2002, 08:45:54 : Search time 2565.15 Seconds

(without alignments)  
12879.875 Million cell updates/sec

Title: US-09-924-400-303

Perfect score: 2040

Sequence: 1 atggtgctgagtgatc.....aaaaaaaaaaaaaa 2040

Scoring table: OLIGO NUC  
Gapop 60.0 , Gapext 60.0

Searched: 16154066 seqs, 8097743376 residues

Word size : 15

Total number of hits satisfying chosen parameters: 1430706

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Listing first 45 summaries

Database :  
EST:  
1: em\_estba:  
2: em\_esthum:  
3: em\_estin:  
4: em\_estnu:  
5: em\_estov:  
6: em\_estpl:  
7: em\_estro:  
8: em\_estc:  
9: gb\_estc:  
10: gb\_estl:  
11: gb\_estl:  
12: gb\_estl:  
13: gb\_estl:  
14: gb\_estl:  
15: em\_estfun:  
16: em\_estom:  
17: gb\_gss:  
18: em\_gss\_hum:  
19: em\_gss\_inv:  
20: em\_gss\_pln:  
21: em\_gss\_vrt:  
22: em\_gss\_fun:  
23: em\_gss\_mam:  
24: em\_gss\_mug:  
25: em\_gss\_other:  
26: em\_gss\_pro:  
27: em\_gss\_rtd:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Length	ID	Description
1	184	9.0	521 17	AQ204617 HS-3229-B
2	141	6.9	865 12	BF676987 602084215
3	140	6.9	451 9	A1804733 cu42b03.x
4	137	6.7	289 9	AA533501 n196a04.s
5	129	6.3	531 17	AQ615477 HS-5144-B
6	117	5.7	621 14	BM763942 K-EST0045

7	117	5.7	633 14	BM763453 K-EST0044
8	117	5.7	817 14	BM443373 ACBNCOURT
9	89	4.4	400 17	AQ124119 HS-3122-A
10	87	4.3	399 17	AQ030111 RPI11-39
11	87	4.3	544 9	AL703938 DRP2686E
12	79	3.9	279 13	B1461255 603206584
13	73	3.6	385 17	AQ063365 CIT-HSP-2
14	59	2.9	707 17	AQ045796 Pan tCt01
15	57	2.8	607 17	B48260 RPI11-6K4
16	52	2.5	380 12	BF329652 RCG-BM027
17	50	2.5	592 17	AQ372700 RPI11-14
18	49	2.4	495 17	AQ469831 CITB1-E1-
19	49	2.4	557 17	AQ469663 CITB1-E1-
20	49	2.4	667 17	AG156382 Pan tCt01
21	49	2.4	697 17	AQ030113 RPI11-39
22	47	2.3	187 10	BE069869 CH1-BT039
23	47	2.3	476 17	AQ392059 CITB1-E1-
24	46	2.3	400 17	AQ057106 CIT-HSP-2
25	45	2.2	894 12	BF675049 602136643
26	44	2.2	460 17	AQ360298 HS-5035-A
27	41	2.0	710 17	AG165908 Pan tCt01
28	40	2.0	503 17	B55862 CIT-HSP-200
29	39	1.9	1011 17	AQ090910 HS-2055-B
30	38	1.9	458 17	AQ247090 HS-2055-B
31	37	1.8	424 17	AQ763344 HS-3162-A
32	37	1.8	624 12	BG720647 602692528
33	36	1.8	652 17	AG054405 Pan tCt01
34	35	1.7	156 9	A1349163 7e73c06.x
35	35	1.7	157 9	A1251211 qv38h06.x
36	35	1.7	160 9	A1305627 qv72f03.x
37	35	1.7	166 9	A1343314 lb93912.x
38	35	1.7	184 10	AW302925 xr86907.x
39	35	1.7	199 10	AW302925 xr86908.x
40	35	1.7	224 9	A1344928 cb01a04.x
41	35	1.7	232 9	A1335592 cb94d12.x
42	35	1.7	239 9	A1344933 cb01a11.x
43	35	1.7	239 9	A1344936 cb01b03.x
44	35	1.7	250 9	A1335449 lb79f03.x
45	35	1.7	360 9	A1494279 qy98c11.x

## ALIGNMENTS

RESULT 1  
LOCUS AQ204617 521 bp DNA linear GSS 17-SEP-1998  
DEFINITION HS-3229-B1-G12-T7 CIT Approved Human Genomic Sperm Library D Homo  
sapiens genomic clone Plate=3229 Col=23 Row=N, DNA sequence.  
ACCESSION AQ204617  
VERSION AQ204617.1 GI:3615187  
KEYWORDS GSS.  
SOURCE human.  
ORGANISM Homo sapiens

REFERENCE Eukaryote: Metazoa: Chordata: Craniata: Vertebrata: Euteleostomi:  
Mammalia: Eutheria: Primates: Catarrhini: Hominoidea: Homo.  
AUTHORS Mahalirats,G.G., Wallace,J.C., Smith,K., Swartzell,S., Holzman,T.,  
Keller,A., Shaker,R., Furlong,J., Young,J., Zhao,S., Adams,M.D. and  
Hood,L.

TITLE Sequence-tagged connectors: A sequence approach to mapping and  
scanning the human genome  
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 96 (17), 9739-9744 (1999)  
COMMENT High Throughput Sequencing Center  
Contact: Mahalirats GC, Wallace JC, Hood L  
University of Washington  
401 Queen Anne Avenue North, Seattle, WA 98109, USA  
Tel: (206) 616-3618  
Fax: (206) 616-3887  
Email: jwallace@u.washington.edu  
Sequence Tagged Connector  
Plate: 3229 row: N column: 23

④ Int Summary





Query Match 3.9%; Score 79; DB 13; Length 279;  
 Best Local Similarity 100.0%; Pred. No. 5.4e-10;  
 Matches 79; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 ATGCGTGTGAGTTCATTCATCCGCGCTGCTCTTGTGAGAAAGCAATTTGCTC 60  
 |||||||  
 Db 84 ATGCGTGTGAGTTCATTCATCCGCGCTGCTCTTGTGAGAAAGCAATTTGCTC 25  
 |||||||

QY 61 AGAGCAAGATGGCCAACT 79  
 |||||||  
 Db 24 AGAGCAAGATGGCCAACT 6  
 |||||||

RESULT 13  
 A0063365 385 bp DNA linear GSS 31-JUL-1998  
 LOCUS CIT-HSP-2348P17.TR CIT-HSP Homo sapiens genomic clone 2348P17, DNA  
 DEFINITION  
 ACCESSION A0063365  
 VERSION A0063365.1 GI:3361196  
 KEYWORDS GSS.

SOURCE  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 1 (bases 1 to 385)  
 Adams,M.D., Rounsley,S.D., Zhao,S., Field,C.E., Bass,S., Linher,K.,  
 Golden,K., Berry,K., Granger,D., Sun,E., Wible,C., Shizuya,H.,  
 Simon,M. and Venter,J.C.  
 Use of a random BAC End Sequence Database for Sequence-Ready Map  
 Building (1998)  
 Unpublished (1998)  
 Other\_GSSs: CIT-HSP-2348P17.TR  
 Contact: Mark Adams  
 Department of Eukaryotic Genomics  
 The Institute for Genomic Research  
 9712 Medical Center Dr., Rockville, MD 20850, USA  
 Tel: 301 838 0200  
 Fax: 301 838 0208  
 Email: madsam@tigr.org  
 Clones are available from Research Genetics (info@resgen.com). BAC  
 end search page:  
 http://www.tigr.org/tdb/humgen/bac\_end\_search/bac\_end\_search.html.  
 Seq primer: M13 Reverse  
 Class: BAC ends.

FEATURES  
 source  
 1..385  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /clone="2348P17"  
 /clone\_lib="CIT-HSP"  
 /sex="Male"  
 /cell\_type="Sperm"  
 /note="Vector: pBelobAC11, site\_1: HindIII, site\_2:  
 HindIII"

BASE COUNT 118 a 53 c 79 g 135 t

ORIGIN

Query Match 3.6%; Score 73; DB 17; Length 385;  
 Best Local Similarity 100.0%; Pred. No. 1.1e-08;  
 Matches 73; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1408 AGAATTGGCAATAGTTCTGACTACAAAGAAAAAGATGCCAAATATCTTTCGAA 1467  
 |||||||  
 Db 189 AGAATTGGCAATAGTTCTGACTACAAAGAAAAAGATGCCAAATATCTTTCGAA 248  
 |||||||

QY 1468 AACAGCAACCCAG 1480  
 |||||||

Db 249 AACAGCAACCCAG 261  
 |||||||

RESULT 14

AC045796/c  
 LOCUS AC045796 707 bp DNA linear GSS 02-NOV-2001  
 DEFINITION Pan troglodytes DNA, clone: PTB-024N04.R, genomic survey sequence.  
 ACCESSION AC045796  
 VERSION AC045796.1 GI:16582688  
 KEYWORDS GSS.

SOURCE  
 ORGANISM Pan troglodytes male lymphoblast DNA, clone\_11b:PTB Chimpanzee Male  
 Pan troglodytes  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Pan.

REFERENCE  
 AUTHORS Fujiyama,A., Hattori,M., Toyoda,A., Taylor,T.D., Yada,T.,  
 Toki,Y., Watanabe,H. and Sakaki,Y.  
 BAC end sequences of library PTB  
 Unpublished  
 2 (bases 1 to 707)  
 Fujiyama,A., Hattori,M., Toyoda,A., Taylor,T.D., Yada,T.,  
 Toki,Y., Watanabe,H. and Sakaki,Y.  
 Direct Submission  
 Submitted (02-AUG-2001) Asao Fujiyama, The Institute of Physical  
 and Chemical Research (RIKEN), Genomic Sciences Center (GSC);  
 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan  
 (E-mail:chibbes@sc.riken.go.jp, URL:http://ngp.gsc.riken.go.jp/,  
 Tel:81-45-508-9111, Fax:81-45-503-9170)  
 Clones are derived from the chimpanzee BAC library PTB This BAC  
 was generated during the R&D process and may have higher chance of  
 clone tracking errors.  
 PRIMERS

COMMENT  
 Sequencing: M13rev  
 LIBRARY  
 Vector : pKS145  
 R.Site 1 : SacI  
 R.Site 2 : SacI  
 location/Qualifiers  
 1..707  
 /organism="Pan troglodytes"  
 /db\_xref="taxon:9598"  
 /clone="PTB-024N04.R"  
 /sex="male"  
 /cell\_type="lymphoblast"  
 /clone\_lib="PTB Chimpanzee Male BAC library"

BASE COUNT 233 a 145 c 85 g 217 t

ORIGIN

Query Match 2.9%; Score 59; DB 17; Length 707;  
 Best Local Similarity 100.0%; Pred. No. 1.1e-05;  
 Matches 59; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1956 GGAAGAAATTCCTAGTCACTGAGCTAGACACATGAAATCATGAGACCACTAA 2014  
 |||||||  
 Db 226 GGAAGAAATTCCTAGTCACTGAGCTAGACACATGAAATCATGAGACCACTAA 168  
 |||||||

RESULT 15  
 B48260/c  
 LOCUS B48260 607 bp DNA linear GSS 08-APR-1999  
 DEFINITION RPI11-6K4.TV RPI1-11 Homo sapiens genomic clone RPI1-11-6K4, DNA  
 sequence.  
 ACCESSION B48260  
 VERSION B48260.1 GI:2600497  
 KEYWORDS GSS.

SOURCE  
 ORGANISM human.  
 Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 1 (bases 1 to 607)  
 Adams,M.D., Rounsley,S.D., Field,C.E., Bass,S., Linher,K., Golden  
 K., Berry,K., Granger,D., Sun,E., Wible,C., de Jong,P. and Venter  
 J.C.  
 Use of BAC End Sequences for Sequence-Ready Map Building  
 Unpublished (1997)  
 Contact: Mark Adams

⑦ Int Summary



```

VERSION      A1344933.1  GI:4082139
KEYWORDS
SOURCE
ORGANISM      Homo sapiens
                Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE     1 (bases 1 to 239)
AUTHORS      NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap/
TITLE        National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
                Tumor Gene Index
JOURNAL      Unpublished (1997)
COMMENT      Contact: Robert Strausberg, Ph.D.
                Email: cga@bbs-remail.nih.gov
                CDNA Library Preparation: David B. Krizman, Ph.D.
                DNA Sequencing by: I.M.A.G.E. Consortium, LLNL
                DNA distribution: NCI-CGAP clone distribution information can be
                found through the I.M.A.G.E. Consortium/LLNL at:
                www-bio.llnl.gov/dbp/image/image.html
                Insert Length: 291 Std Error: 0.06
                Seq primer: -400P from Gibco.
                Location/Qualifiers
                1. 239
                /organism="Homo sapiens"
                /db_xref="taxon:9606"
                /clone="IMAGE:2052284"
                /clone_1lb="NCI-CGAP_Lu26"
                /tissue_type="invasive adenocarcinoma"
                /dev_stage="adult"
                /lab_host="DH10B"
                /note="Organ: Lung; Vector: PAMP1; mRNA made from lung
                adenocarcinoma tissue, cDNA made by oligo-dT priming.
                directionally cloned. Size selected on agarose gel,
                average insert size 500 bp. Primary library,
                non-amplified."

BASE COUNT    119 a      48 c      40 g      32 t
ORIGIN
Query Match   1.7%: Score 35; DB 9; Length 239;
Best Local Similarity 100.0%; Pred. No. 27;
Matches 35; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2006 GCCAGCTAAAAAAAAAAAAAAAAAAAAA 2040
Db 146 GCCAGCTAAAAAAAAAAAAAAAAAAAAA 180

RESULT 43
LOCUS      A1344936      239 bp      mRNA      linear      EST 30-DEC-1998
DEFINITION  U01003.x1 NCI-CGAP_Lu26 Homo sapiens CDNA clone IMAGE:2052284 3',
                mRNA sequence.
ACCESSION   A1344936
VERSION     A1344936.1  GI:4082142
KEYWORDS    EST.
SOURCE      human.
ORGANISM    Homo sapiens
                Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE     1 (bases 1 to 239)
AUTHORS      NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap/
TITLE        National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
                Tumor Gene Index
JOURNAL      Unpublished (1997)
COMMENT      Contact: Robert Strausberg, Ph.D.
                Email: cga@bbs-remail.nih.gov
                CDNA Library Preparation: David B. Krizman, Ph.D.
                DNA Sequencing by: I.M.A.G.E. Consortium, LLNL
                DNA distribution: NCI-CGAP clone distribution information can be
                found through the I.M.A.G.E. Consortium/LLNL at:
                www-bio.llnl.gov/dbp/image/image.html
                Seq primer: -400P from Gibco.

```

```

FEATURES
source
Location/Qualifiers
1. 239
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2052284"
/clone_1lb="NCI-CGAP_Lu26"
/tissue_type="invasive adenocarcinoma"
/dev_stage="adult"
/lab_host="DH10B"
/note="Organ: Lung; Vector: PAMP1; mRNA made from lung
adenocarcinoma tissue, cDNA made by oligo-dT priming.
directionally cloned. Size selected on agarose gel,
average insert size 500 bp. Primary library,
non-amplified."

BASE COUNT    119 a      48 c      40 g      32 t
ORIGIN
Query Match   1.7%: Score 35; DB 9; Length 239;
Best Local Similarity 100.0%; Pred. No. 27;
Matches 35; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2006 GCCAGCTAAAAAAAAAAAAAAAAAAAAA 2040
Db 146 GCCAGCTAAAAAAAAAAAAAAAAAAAAA 180

RESULT 44
LOCUS      A1335449      250 bp      mRNA      linear      EST 29-DEC-1998
DEFINITION  U01003.x1 NCI-CGAP_Lu26 Homo sapiens CDNA clone IMAGE:2060573 3',
                mRNA sequence.
ACCESSION   A1335449
VERSION     A1335449.1  GI:4072376
KEYWORDS    EST.
SOURCE      human.
ORGANISM    Homo sapiens
                Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE     1 (bases 1 to 250)
AUTHORS      NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap/
TITLE        National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
                Tumor Gene Index
JOURNAL      Unpublished (1997)
COMMENT      Contact: Robert Strausberg, Ph.D.
                Email: cga@bbs-remail.nih.gov
                CDNA Library Preparation: David B. Krizman, Ph.D.
                DNA Sequencing by: I.M.A.G.E. Consortium, LLNL
                DNA distribution: NCI-CGAP clone distribution information can be
                found through the I.M.A.G.E. Consortium/LLNL at:
                www-bio.llnl.gov/dbp/image/image.html
                Seq primer: -400P from Gibco.
                High quality sequence stop: 240.
                Location/Qualifiers
                1. 250
                /organism="Homo sapiens"
                /db_xref="taxon:9606"
                /clone="IMAGE:2060573"
                /clone_1lb="NCI-CGAP_Lu26"
                /tissue_type="invasive adenocarcinoma"
                /dev_stage="adult"
                /lab_host="DH10B"
                /note="Organ: Lung; Vector: PAMP1; mRNA made from lung
                adenocarcinoma tissue, cDNA made by oligo-dT priming.
                directionally cloned. Size selected on agarose gel,
                average insert size 500 bp. Primary library,
                non-amplified."

BASE COUNT    136 a      43 c      41 g      30 t
ORIGIN
Query Match   1.7%: Score 35; DB 9; Length 250;
Best Local Similarity 100.0%; Pred. No. 26;
Matches 35; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

9. Int Summary